Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SELE | P16581 | 1/20 | 0.34 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24227162 | 0.76 | SELE (0.35) | LMNASELEVCAM1ALDH1A1ENPP1 | |
| SCHEMBL16624814 | 0.76 | SELE (0.35) | LMNASELEVCAM1ALDH1A1ENPP1 | |
| SCHEMBL24582094 | 0.75 | KDM4E (0.42) | ALDH1A1 | |
| SCHEMBL19294662 | 0.72 | TSHR (0.33) | SELEVCAM1 | |
| SCHEMBL23911227 | 0.71 | SELE (0.34) | LMNASELEVCAM1ALDH1A1ENPP1 | |
| SCHEMBL25921193 | 0.71 | ENPP1 (0.38) | LMNASELEVCAM1ALDH1A1ENPP1 | |
| SCHEMBL16719274 | 0.70 | FFAR1 (0.38) | LMNAALDH1A1 | |
| SCHEMBL18393052 | 0.70 | RECQL (0.39) | RECQLLMNA | |
| SCHEMBL2058832 | 0.70 | SELE (0.34) | LMNASELEVCAM1ALDH1A1ENPP1 | |
| SCHEMBL20977931 | 0.70 | SELE (0.34) | LMNASELEVCAM1ALDH1A1ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117157297-A | PRMT5 inhibitors | 上海齐鲁制药研究中心有限公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-2148880-B1 | P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8093383-B2 | P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | RECQL 1713/4885LMNA 4176/4885SELE 4744/4885 |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | RECQL 1713/4885LMNA 4176/4885SELE 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.